2seventy bio, Inc. (NasdaqGM: TSVT)
Health Care · Biotechnology · US
$—
— today · — 1Y
2seventy bio, Inc. (NasdaqGM: TSVT) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores 2seventy bio, Inc. across four factors: quality 17/100, growth 0/100. Its strongest factor is quality.
TSVT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $48.37M
- P/E
- —
- EPS
- -0.08
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 65
- Next earnings
- —
About 2seventy bio, Inc.
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
- ISIN
- US9013841070
- Founded
- 2021
- Listed since
- Nov 3, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.